Bluejay Diagnostics Inc. (Bluejay Diagnostics (BJDX)) is having a very good Tuesday. The medical diagnostics company announced a strategic partnership with Argonaut Manufacturing Services to scale up production and distribution of its Symphony platform, and investors are cheering: shares surged more than 200% in premarket trading.

Bluejay is focused on near-patient testing for critical care, and its Symphony System is designed to be a cost-effective, rapid testing platform for sepsis triage and monitoring. Sepsis is a life-threatening condition where early detection is crucial, and Bluejay's first product candidate — an IL-6 Test — can deliver accurate results in about 20 minutes from sample to result. That speed could help doctors make faster triage and treatment decisions.

But there's a catch: Bluejay doesn't yet have regulatory clearance from the U.S. Food and Drug Administration. So while the technology is promising, it can't be marketed as a diagnostic product in the U.S. until the FDA gives the green light. The partnership with Argonaut is partly about getting ready for that eventual approval.

The collaboration is designed to establish scalable U.S.-based manufacturing capabilities that align with Bluejay's clinical development programs and future commercialization goals. That's a big deal because Bluejay currently relies on overseas manufacturing, which comes with risks — supply chain disruptions, shipping delays, and import tariffs. By moving production to the U.S., Bluejay gains more operational control, better business continuity, and a more secure supply chain.

In addition to manufacturing, the partnership aims to strengthen Bluejay's commercial infrastructure for broader product distribution across the U.S. That means when — and if — the Symphony System gets FDA clearance, Bluejay will be ready to get it into hospitals quickly.

For now, the market is betting that this partnership is a step in the right direction. Bluejay Diagnostics shares were up 212.90% at $6.79 in premarket trading Tuesday. It's a big move for a company that's still pre-revenue, but the potential market for rapid sepsis testing is enormous, and having a U.S.-based manufacturing partner could be a key differentiator.